Probenecid

Probenecid has been studied in 1 paper since 2025: none in people yet, 1 review. No study of it in people or animals has been published yet. The newest paper, Jan 17, 2025: “Trends in drug repurposing: Advancing cardiovascular disease management in geriatric populations”.

Intervention

1 paper studies it1 more mentions it1 findingUpdated

PubChemChEBI

See all 2 papers on probenecid

At a glance

The findings reach worms or flies, none yet in people. 1 lab in 1 country; 17 trials, none about aging, 8 with no results posted.

Worms or flies: a single group. Cells, mice and humans: nothing yet.
  • 1 lab in 1 country
  • 17 trials, none about aging, 8 with no results posted
  • Funder: Natural Sciences and Engineering Research Council

What did studies of probenecid find?

1

Studies of probenecid measured one outcome, Neuronal efflux transporter activity.

Neuronal efflux transporter activity

downin L. stagnalis1

1 study
  1. Probenecid inhibits neuronal efflux transporter activity in L. stagnalis (5(6)-carboxyfluorescein removal assay).

    “we provide, for the first time, physiological evidence for the existence of probenecid-, MK571- and glutathione-sensitive efflux transporters in (gastropod) neurons”

    Model organisms5(6)-carboxyfluorescein removal assayneuron

    Physiological and pharmacological characterization of a molluscan neuronal efflux transporter; evidence for age-related transporter impairment

    The Journal of experimental biology

Who is developing probenecid?

3 companies: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Incyte and Guangdong Raynovent Biotech.

Companies
  • Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyPhase 1
  • IncytePhase 1
  • Guangdong Raynovent BiotechPhase 1

Trial sponsors

Latest